GT Biopharma Inc (GTBP) Stock Analysis

GT Biopharma Inc (GTBP) is a publicly traded company in the HEALTHCARE sector. It trades at $0.47, carries a market capitalization of $15.94M. This page summarizes the public market data, fundamentals, and frequently asked questions for GTBP, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

GT Biopharma Inc currently has a Neutral sentiment score of -0.09.

About GT Biopharma Inc

GT Biopharma Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative immuno-oncology therapies, utilizing its proprietary Tri-specific Killer Engager (TriKE) technology platform to enhance immune responses against cancer. Headquartered in Beverly Hills, California, the company is dedicated to addressing critical unmet medical needs in oncology, with a robust pipeline designed to empower the immune system in targeting and eliminating malignant cells. As it p...

GNG Research Analysis

GNG Research scores GT Biopharma Inc (GTBP) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for GTBP.

Frequently Asked Questions

Does GTBP pay dividends?

GT Biopharma Inc (GTBP) does not currently pay a regular dividend.

What is GTBP's market cap?

GT Biopharma Inc (GTBP) has a market capitalization of $15.94M with a current stock price of $0.47.